Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081603 | 1.00 | NR3C1 (0.77) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL8197072 | 0.91 | NR3C1 (0.75) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL8068364 | 0.87 | NR3C1 (1.00) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL7899988 | 0.87 | NR3C1 (0.69) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL7081817 | 0.86 | NR3C1 (0.70) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL8674574 | 0.86 | NR3C1 (0.70) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL7894330 | 0.86 | NR3C1 (0.62) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL7903153 | 0.86 | NR3C1 (0.65) | NR3C1CYP3A4PGRARLMNA | |
| SCHEMBL8138913 | 0.85 | NR3C1 (0.66) | NR3C1CYP3A4PGRARUSP2 | |
| SCHEMBL7894324 | 0.85 | NR3C1 (0.68) | NR3C1CYP3A4PGRARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6197761-B1 | ANTIINFLAMMATORY, ANTALLERGEN AGENTS | GLAXO WELLCOME INC. | 2001-03-06 | — | — | US | claimed |
| EP-0876392-B1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | claimed |
| EP-0876392-A1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-11-11 | — | — | EP | claimed |
| WO-1997024365-A1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1997-07-10 | — | — | WO | claimed |
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2016-01-21 | — | — | US | disclosed |
| US-6197761-B1 | ANTIINFLAMMATORY, ANTALLERGEN AGENTS | GLAXO WELLCOME INC. | 2001-03-06 | — | — | US | disclosed |
| EP-0876392-B1 | LACTONE DERIVATIVES OF 17.BETA.-CARBOXY, CARBOTHIO AND AMIDE ANDROSTANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ADRB2, ADRA2A, ADRA2B | NR3C1 15/4885CYP3A4 301/4885PGR 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.